Publications by authors named "Glenn Doherty"
Article Synopsis
- The study aims to evaluate how diabetes treatment satisfaction varies by ethnicity among individuals with type 2 diabetes who have poor glycaemic control, highlighting a gap in current data about patient satisfaction in this context.
- A total of 346 participants took part in an 8-month clinical trial, completing the Diabetes Treatment Satisfaction Questionnaire (DTSQ) to assess their treatment satisfaction, which was found to be high overall.
- The results indicated that treatment satisfaction was especially high among Pacific peoples and older individuals, even though many participants had insufficient glucose-lowering therapy and suboptimal glycaemic control.
Background: Understanding which group of patients with type 2 diabetes will have the most glucose lowering response to certain medications (which target different aspects of glucose metabolism) is the first step in precision medicine.
Aims: We hypothesized that people with type 2 diabetes who generally have high insulin resistance, such as people of Māori/Pacific ethnicity, and those with obesity and/or hypertriglyceridemia (OHTG), would have greater glucose-lowering by pioglitazone (an insulin sensitizer) versus vildagliptin (an insulin secretagogue).
Methods: A randomised, open-label, two-period crossover trial was conducted in New Zealand.
INTRODUCTION Macroalbuminuria in people with type 2 diabetes is common among Pasifika peoples and is associated with end-stage kidney disease and major cardiovascular disease. AIM In a primary care practice catering for Pasifika people, to determine the time after first recognition of macroalbuminuria to the occurrence of major cardiovascular and renal events, and to examine the relationship with retinopathy status. METHODS In a retrospective observational cohort study, we documented the occurrence of major cardiovascular events and amputations, end-stage kidney disease and death in 115 people with type 2 diabetes reviewed by a specialist diabetes physician at the Langimalie Tongan Health practice between 2005 and 2018.
View Article and Find Full Text PDFBackground: The impact of remdesivir (RDV) on mortality rates in coronavirus disease 2019 (COVID-19) is controversial, and the mortality effect in subgroups of baseline disease severity has been incompletely explored. The purpose of this study was to assess the association of RDV with mortality rates in patients with COVID-19.
Methods: In this retrospective cohort study we compared persons receiving RDV with those receiving best supportive care (BSC).
Introduction: There is emerging evidence for stratified glucose-lowering responses to certain oral medications for type 2 diabetes (T2D) by individual characteristics. The objective of this study was to test whether glycaemic response to representative treatments of dipeptidyl peptidase-4 inhibitors (vildagliptin) and thiazolidinediones (pioglitazone) varies according to ethnicity, gender, baseline obesity, triglyceride level or genetic variation.
Methods: This is a multicentre, two-period, two-treatment, open-label, randomised cross-over trial of vildagliptin and pioglitazone as second-line or third-line therapy in patients with T2D who have suboptimal glycaemic control on metformin and/or sulfonylurea therapy.